New approach needed to tackle rising drug prices | bambinoides.com

New approach needed to tackle rising drug prices

The proliferation of rising drug prices is increasing pressures on public health spending and calling into question the pharmaceutical industry’s pricing strategies. Governments need to work with the industry to define a new approach to the development and use of new health technologies for delivering more affordable money treatments.

 

The proliferation of high-cost medicines and rising drug prices are increasing pressures on public health spending and calling into question the pharmaceutical industry’s pricing strategies. Governments need to work with the industry and regulators to define a new approach to the development and use of new health technologies that encourages innovation while also delivering more affordable and value for money treatments, according to a new OECD report.

 

New Health Technologies: Managing Access, Value and Sustainability says that pharmaceutical spending is increasingly skewed towards high-cost products. The launch prices of drugs for cancer and rare diseases are rising, sometimes without a commensurate increase in health benefits for patients. For instance in the United States, the launch price of oncology drugs per life-year gained has been multiplied by four in less than 20 years – in constant terms – and now exceeds USD 200 000.

 

Payers, such as insurers or public health providers, are also increasingly struggling to pay for high-cost medicines targeting very small populations, which are expected to proliferate with the development of precision medicine. On the other side of spectrum, new treatments for hepatitis which are very effective and cost-effective in the long-term but target a wide population, are unaffordable to many who would benefit in almost all OECD countries because of their high budget impact.

 

The prices paid for technologies must reflect their real-world health benefits compared to alternatives, and be adjusted based on evidence about their actual impact. Payers must be equipped with the necessary powers to adjust prices and withdraw payment for ineffective technologies.

A rebalancing of the negotiating powers of payers and manufacturers is needed, says the report. This could be through increased transparency and co-operation between payers and international joint procurement initiatives, as tested in Europe and Latin America. Pricing agreements, which link the final price paid to the actual performance of the drug, as used in Italy and England, may also be effective if management and administration costs are controlled and the clinical data and evidence collected made widely available to the scientific community.

 

The report, which will be discussed at an OECD meeting for Ministers of Health on “The Next Generation of Health Reforms” in Paris on 17 January, highlights other challenges facing the adoption of new technologies. Investment in R&D to treat neglected diseases, such as HIV/AIDS or tuberculosis, fight antimicrobial resistance and address dementia has also become less attractive as their profitability is lower. The incentives for private investment in these areas should be strengthened.

 

Many biomedical technologies are today approved and adopted based on limited evidence of their safety and effectiveness. Assessment of their performance in real world conditions is rare. This compromises safety, is wasteful and no longer sustainable.

 

More efforts are also needed to harness the potential of health data more effectively. Use of personal health data creates major opportunities for health system improvement, research and disease surveillance, but requires the right governance frameworks to realise these benefits while managing the privacy risks.

 

oecd.org


The views expressed are not necessarily those of the publisher or bambinoides.com. Images accompanying posts are either owned by the author of said post or are in the public domain and included by the publisher of the blog bambinoides.com on its initiative.

Leave a comment

You must be Logged in to post comment.

© 2012-2017 - Copyright - bambinoides.com is not liable for the content of external web pages

© 2012-2017 - © Copyright / Copyright Disclaimer Under Section 107 of the Copyright Act 1976, allowance is made for "fair use" for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. Non-profit, educational or personal use tips the balance in favor of fair use. / Derechos Reservados & CLÁUSULA DE EXENCIÓN DE RESPONSABILIDAD: bambinoides.com (El BLOG), tiene un carácter divulgativo, informativo y de entretenimiento, poniendo a disposición de todos, informaciones, noticias, reportajes, material audio-visivo y gráfico de contenido variado y sugestivo con el único interés de provocar un sano debate entre amigos e interesados. De no ser especificado, los artículos, comentarios y/o introducciones son escritos y propiedad de Antonio-"Bambino" Maldonado-Boschetti (indistintamente con siglas AMB - ◊◊B◊◊). Además, en EL BLOG se evidencian vínculos y se divulga información originaria de numerosas fuentes por lo que ni El BlOG ni Antonio-"Bambino" Maldonado-Boschetti son particular y específicamente responsables del contenido de aquellas.-- USO JUSTO (Fair Use): Descargo de Responsabilidad: bambinoides.com y/o Antonio-"Bambino" Maldonado-Boschetti (AMB/◊◊B◊◊) no es (son) propietario de la mayor parte de los audios-vídeos que forma parte de la Galería de Vídeos de bambinoides.com los cuales pertenecen a numerosos autores, artistas y/o productores. Aviso y reclamo que los derechos de autor bajo la sección 107 del Copyright Act 1976 (USA) permiten el uso y divulgación de este material con “USO JUSTO” para propósitos tales como crítica, comentario, noticias, enseñanza, becas e investigación. El “USO JUSTO” (Fair Use) es un uso lícito y permitido por la Ley de Derechos de Autor, que de lo contrario podría constituir una violación. El uso sin fines de lucro, educativo, noticioso o informativo, o personal inclina la balanza a favor del “uso justo" por parte de bambinoides.com.-- La información y el contenido "multimedia" publicado por EL BLOG son de carácter público, libre y gratuito. Pueden ser reproducidos con la obligatoriedad de citar la fuente: http://www.bambinoides.com y a cada autor en particular. -- Los comentarios y reacciones de los lectores publicados en los "posts" son de la entera responsabilidad de quien los emite; EL BLOG intenta implementar un mecanismo de auto regulación y/o puede decidir no publicar comentarios que constituyan abuso o que lesionen el buen gusto y los derechos de otros. -- Se pueden enviar colaboraciones gratis directamente a bambino@bambinoides.com quien se reserva el derecho de publicación.
All photos accompanying posts are either owned by the author of said post or are in the public domain and included by the blog bambinoides.com on its initiative.

Creative Commons Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Bambinoides.com está disponible bajo una licencia “Creative Commons” Reconocimiento-No comercial 4.0. Cualquier reconocimiento debe ser a bambinoides.com y a cada autor/publicación en particular.

WP-Backgrounds Lite by InoPlugs Web Design and Juwelier Schönmann 1010 Wien
Confrontando la información, - el pasado y el presente...
"Estudia el pasado si quieres pronosticar el futuro" (Confucio)
“La historia es en realidad el registro de crímenes, locuras y adversidades de la humanidad” (E. Gibbon)